Example of the integrated approach to treatment of the patient with disseminated stomach cancer taking into account of modern clinical trends


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents a clinical case of successful complex treatment of a patient with HER2-negative disseminated gastric cancer with the presence of disseminated tumor cells (DTCs) in the bone marrow. The life expectancy of the patient from the start of treatment is 32+ months. The mentioned observation demonstrates: 1) the possibility of performing surgical treatment in selected patients with disseminated gastric cancer; 2) the need to re-determine HER2-status in metastases of gastric cancer due to the possibility of its change in the treatment process; 3) high efficacy of trastuzumab in HER2-positive stomach cancer; and 4) prognostic role of the presence of DTCs in the bone marrow and their dynamics during the treatment.

Full Text

Restricted Access

About the authors

N. S Besova

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

Email: besovans@mail.ru
PhD, Senior Researcher at the Department of Chemotherapy

E. V Trusilova

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

E. S Obarevich

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

N. N Tupitsyn

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

V. A Gorbunova

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

M. M Davydov

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

N. Ts Drobot

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

B. A Perfiliev

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

O. A Malikhova

FSBI “NMRC of Oncology n.a. N.N. Blokhin" of RMH

References

  1. Chau I., Ashley S., Cunningham D. Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J. Clin. Oncol. 2009;27:e3-4.
  2. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 1965;64:31-49.
  3. Wagner A.D., Grothe W., Haerting J., Kleber G., Grothey A., Fleig W.E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol.2006;24:2903-909.
  4. Tay S.T., Leong S.H., Yu K., Aggarwal A., Tan S.Y, Lee C.H., Wong K., Visvanathan J., Lim D., Wong W.K., Soo K.C., Kon O.L., Tan P. A combined comparative genomic hy-bridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res. 2003;63:3309-16.
  5. Kim B., Bang S., lee S., Kim S., Jung Y, Lee C., Choi K., Lee S.G., Lee K., Lee Y., Kim S.S., Yeom Y.I., Kim Y.S., Yoo H.S., Song K., Lee I. Expression profiling and sub-typespecific expression of stomach cancer. Cancer Res. 2003; 63:8248-55.
  6. Chen X., Leung S.Y., Yuen S.T., Chu K.M., Ji J., Li R., Chan A.S., Law S., Troyanskaya O.G., Wong J., So S., Botstein D., Brown P.O. Variation in gene expression patterns in human gastric cancers. Mol. Biol.Cell. 2003;14:3208-15.
  7. Boussioutas A., Li H., Liu J., Waring P., Lade S., Holloway A.J., Taupin D., Gorringe K., Haviv I., Desmond P.V., Bowtell D.D. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res. 2003;63: 2569-77.
  8. Lee H.S, Cho S.B., Lee H.E., Kim M.A., Kim J.H., Park D.J., Kim J.H., Yang H.K., Lee B.L., Kim W.H. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin. Cancer Res. 2007;13:4154-63.
  9. Tan I.D., Ivanova T., Lim K.H., Ong C.W., Deng N., Lee J., Tan S.H., Wu J., Lee M.H., Ooi C.H., Rha S.Y., Wong W.K., Boussioutas A., Yeoh K.G.,So J., Yong W., Tsuburaya A., Grabsch H., Toh H.C., Rozen S., Cheong J.H., Noh S.H., Wan W.K., Ajani J.A., Lee J.U-S., Salto-Tellez M., Tan P Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology. 2011;141(2):476-85.
  10. Lei Z., Tan I.B., Das K., Deng N., Zouridis H., Pattison S., Chua C., Feng Z., Guan Y.K., Ooi C.H., Ivanova T., Zhang S., Lee M., Wu J., Ngo A., Manesh S., Tan E., Teh B.T., So J.B., Goh L.K., Boussioutas A., Lim T.K., Flotow H., Tan P., Rozen S.G. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145(3):554-65.
  11. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma [published online ahead of print July 23, 2014]. Nature. doi:10.1038/ nature13480.
  12. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Rüschoff J., Kang Y.K.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
  13. Kang Y., Kang W.K., Shin D.B., et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion jo 5-FU/cisplatin (FP) as first-line therapy in patient with advanced gastric cancer: Efficacy and safety results. J. Clin. Oncol. 2006;24(18S):abstr 4018.
  14. Cunningham D., Starling N., Rao S., Iveson T., Nicolson M., Coxon F., Middleton G., Daniel F., Oates J., Norman A.R. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 2010;358(1):36-46.
  15. Al-Batran S.E, Hartmann J.T., Probst S., Schmalenberg H., Hollerbach S., Hofheinz R., Rethwisch V, Seipelt G., Homann N., Wilhelm G., Schuch G., Stoehlmacher J., Derigs H.G. Hegewisch-Becker S., Grossmann J., Pauligk C., Atmaca A., Bokemeyer C., Knuth A., Jäger E. Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol. 2008;26:1435-42.
  16. Dank M., Zaluski J., Barone C., et al. Randomized phase 3 trial of irinotecan (CPT-11)+5FU/folinic acid (FA) vs CDDP+5FU in 1st line advanced gastric cancer patients. Proc. Am. Soc. Clin. Oncol. 2005;23(16s):308s(abstr. 4003).
  17. Waters J.S., Norman A., Cunningham D., Scarffe J.H., Webb A., Harper P., Joffe J.K., Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial, Br. J. Cancer. 1999;80:269-72.
  18. Van Cutsem E., Moiseyenko V.M., Tjulandin S., Majlis A., Constenla M., Boni C., Rodrigues A., Fodor M., Chao Y., Voznyi E., Risse M.L., Ajani J.A.; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J. Clin. Oncol. 2006;24:4991-97.
  19. Lorenzen S., Hentrich M., Haberl C, Heinemann V., Schuster T., Seroneit T., Roethling N., Peschel C., Lordick F. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann. Oncol. 2007;18(10):1673-79.
  20. Al-Batran S.E., Hartmann J.T., Hofheinz R., Homann N., Rethwisch V., Probst S., Stoehlmacher J., Clemens M.R., Mahlberg R., Fritz M., Seipelt G., Sievert M., Pauligk C., Atmaca A., Jäger E. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann. Oncol. 200819(11): 1882-87.
  21. Van Cutsem E., Boni C., Tabernero J., Massuti B., Middleton G., Dane F., Reichardt P., Pimentel F. L., Cohn A., Follana P., Clemens M., Zaniboni A., Moiseyenko V., Harrison M., Richards D. A., Prenen H., Pernot S., Ecstein-Fraisse E., Hitier S., Rougier P. Docet-axel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. 2015; 6:149-56.
  22. Wang J., Xu R., Li J., Bai Y., Liu T., Jiao S., Dai G., Xu J., Liu Y., Fan N., Shu Y., Ba Y., Ma D., Qin S., Zheng L., Chen W., Shen L. Randomized multicenter phase III study of modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line chemotherapy for advanced or locally recurrent gastric cancer. Gastric cancer. 2016;19:234-44.
  23. Обаревич Е.С., Бесова Н.С., Давыдов М.М., Стилиди И.С., Горбунова В.А. Изучение эффективности комбинированного подхода к лечению больных диссеминиро-ванным раком желудка. Вестник ФГБУ» РОНЦ им. Н.Н. Блохина». 2016;27(2):83-8.
  24. Yoshida K., Yamaguchi K., Okumura N., Tanahashi T., Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329-38.
  25. Baiocchi G.L., Celotti A., Molfino S., Baggi P., Tarasconi A., Baronio G., Arru L., Gheza F., Tiberio G., Portolani N. Distant nodal metastasis: is it always an unresectable disease? Transl. Gastroenterol. Hepato. 2017;2:1-4.
  26. Jauch K.W., Heiss M.M., Gruetzner U., Funke I., Pantel K., Babic R., Eissner H.J., Riethmueller G., Schildberg F.W. Prognostic Significance of Bone Marrow Micrometastases in Patients With Gastric Cancer. J. Clin. Oncol. 1996;14(6):1810-17.
  27. Naume B., Synnestvedt M., Falk R.S., Wiedswang G., Weyde K., Risberg T., Kersten C., Mjaaland I., Vindi L.,Sommer H.H.,S&tersdal A.B., Rypdal M.C., Bendigtsen Schirmer C., Wist E.A., Borgen E. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. J. Clin. Oncol. 2014;32:3848-52.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies